-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 17, Heji Pharmaceuticals revealed that its first clinical trial application for the oral ITK inhibitor CPI-818, which entered the clinical development stage, was accepted by the NMPA Drug Approval Center, and it was intended to be used for relapsed/refractory T cells.
CPI-818 can strongly inhibit ITK kinase and is highly selective without affecting normal T cell proliferation and immune response
In the first human clinical trials conducted in the United States, South Korea, and Australia, CPI-818 has shown definite efficacy and good safety and tolerability
Note: The original text has been deleted